

By: Blanco

S.B. No. 3005

A BILL TO BE ENTITLED

AN ACT

relating to a study on the use of psychedelic therapies in the treatment of certain conditions.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

SECTION 1. (a) In this Act:

(1) "Department" means the Department of State Health Services.

(2) "Psychedelic therapies" means the use of 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, or ketamine to treat mental health or other medical conditions.

(b) The department, in consultation with Baylor College of Medicine and the Center for Psychedelic Research and Therapy at Dell Medical School at The University of Texas at Austin, shall conduct a study on the use of psychedelic therapies for treatment of post-traumatic stress disorder, depression, and other co-occurring conditions.

(c) In conducting the study, the department shall:

(1) review clinical trials on the efficacy of using psychedelic therapies in the treatment of post-traumatic stress disorder, depression, and other co-occurring conditions;

(2) review current literature regarding the use of psychedelic therapies in the treatment of post-traumatic stress disorder, depression, and other co-occurring conditions;

(3) review actions of the United States Food and Drug

Administration regarding psychedelic therapies for treatment of post-traumatic stress disorder, depression, and other co-occurring conditions;

(4) evaluate treatment guidelines for use of psychedelic therapies to treat post-traumatic stress disorder, depression, and other co-occurring conditions and recommend guidelines and best practices for providers; and

(5) evaluate patient access to current treatment for post-traumatic stress disorder, depression, and other co-occurring conditions and recommend legislative or other actions necessary to ensure patient access to psychedelic therapies following approval by the United States Food and Drug Administration, including considerations of provider availability, affordability, accessibility, training and licensure, and other regulatory requirements.

(d) Not later than December 1, 2026, the department shall submit to the governor, the lieutenant governor, the speaker of the house of representatives, and the chair of the standing committee of each house of the legislature with primary jurisdiction over the department a written report that includes:

(1) the results of the study conducted under this section; and

(2) any recommendations for legislative or other action necessary to ensure patient access to psychedelic therapies for treatment of post-traumatic stress disorder, depression, and other co-occurring conditions after those therapies are approved by the United States Food and Drug Administration.

1           (e)   This Act expires September 1, 2027.

2           SECTION 2.   This Act takes effect September 1, 2025.